MetaCap

Adlai Nortye Group (ANL) vs Design Therapeutics (DSGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Adlai Nortye Group (ANL) has outperformed Design Therapeutics (DSGN) over the past year, gaining 533.3% versus a gain of 8.0%. Design Therapeutics is the larger company by market cap ($577.6 million vs $550.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANL+533.33%DSGN+8.02%
+1188%+547%-93%
Nov 21, 20251 yearNov 20, 2026
ANL-43.00%DSGN+282.20%
+596%+235%-126%
Sep 25, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANL versus DSGN key metrics
MetricANLDSGN
Share price$8.55$9.02
Market cap$550.60M$577.61M
1-day change-5.63%-3.22%
YTD return+502.11%-3.84%
1-year return+533.33%+8.02%
5-year return—-49.27%
EPS (TTM)$-0.66$-1.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-51.87M$-69.79M
52-week high$17.25$17.25
52-week low$0.879$8.21
Distance from 52-week high-50.43%-47.71%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+245.03%+139.14%
Average volume244.74K554.69K
Shares outstanding58.73M64.04M
Employees10960
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANL has outperformed DSGN by 525.3 percentage points over the past year.

About Adlai Nortye Group

ANL stock →

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.

Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees

About Design Therapeutics

DSGN stock →

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees

ANL vs DSGN FAQ

Which is bigger, Adlai Nortye Group or Design Therapeutics?

Design Therapeutics (DSGN) is larger, with a market capitalization of $577.61M compared with $550.60M for Adlai Nortye Group (ANL).

Which stock has performed better over the past year, ANL or DSGN?

ANL returned +533.33% over the past 12 months, compared with +8.02% for DSGN (price return, excluding dividends). Past performance does not predict future results.

Are Adlai Nortye Group and Design Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons